Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (141-150 of 401) with videos related to

Pageof 41
Sort By:
American Heart Journal|July 22, 2019
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarctionShamir R Mehta, David A Wood, Brandi Meeks, et al.
Thrombosis and Haemostasis|January 12, 2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assayWael Sumaya, Rebecca L Daly, Sonal Mehra, et al.
Cardiovascular Diabetology|January 9, 2020
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levelsWilliam A E Parker, Christian Schulte, Temo Barwari, et al.
European Heart Journal|September 27, 2013
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary interventionDániel Aradi, Robert F Storey, András Komócsi, et al.
Journal of the American College of Cardiology|July 13, 2010
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET studyRobert F Storey, Kevin P Bliden, Shankar B Patil, et al.
Journal of the American College of Cardiology|September 14, 2010
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudyRobert F Storey, Dominick J Angiolillo, Shankar B Patil, et al.
Journal of the American College of Cardiology|January 6, 2018
Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by SubgroupsElizabeth A Magnuson, Marc P Bonaca, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|November 6, 2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromesRobert F Storey, Steen Husted, Robert A Harrington, et al.
Journal of the American College of Cardiology|February 10, 2015
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yetWillem J M Dewilde, Paul W A Janssen, Freek W A Verheugt, et al.
Journal of the American College of Cardiology|September 20, 2014
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary reviewWillem J M Dewilde, Paul W A Janssen, Freek W A Verheugt, et al.
Pageof 41

Showing results (141-150 of 401) with videos related to

Sort By:
Pageof 41
American Heart Journal|July 22, 2019
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarctionShamir R Mehta, David A Wood, Brandi Meeks, et al.
Thrombosis and Haemostasis|January 12, 2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assayWael Sumaya, Rebecca L Daly, Sonal Mehra, et al.
Cardiovascular Diabetology|January 9, 2020
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levelsWilliam A E Parker, Christian Schulte, Temo Barwari, et al.
European Heart Journal|September 27, 2013
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary interventionDániel Aradi, Robert F Storey, András Komócsi, et al.
Journal of the American College of Cardiology|July 13, 2010
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET studyRobert F Storey, Kevin P Bliden, Shankar B Patil, et al.
Journal of the American College of Cardiology|September 14, 2010
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudyRobert F Storey, Dominick J Angiolillo, Shankar B Patil, et al.
Journal of the American College of Cardiology|January 6, 2018
Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by SubgroupsElizabeth A Magnuson, Marc P Bonaca, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|November 6, 2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromesRobert F Storey, Steen Husted, Robert A Harrington, et al.
Journal of the American College of Cardiology|February 10, 2015
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yetWillem J M Dewilde, Paul W A Janssen, Freek W A Verheugt, et al.
Journal of the American College of Cardiology|September 20, 2014
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary reviewWillem J M Dewilde, Paul W A Janssen, Freek W A Verheugt, et al.
Pageof 41